Jump to Main Content
- Smider, Vaughn V., et al. Show all 13 Authors
- Proceedings of the National Academy of Sciences of the United States of America 2013 v.110 no.44 pp. 17796-17801
- T-lymphocytes; amino acids; animal models; antibodies; antigens; blood serum; cytotoxicity; half life; ligands; mutants; neoplasm cells; prostatic neoplasms; receptors; solubility; stoichiometry; therapeutics
- ... Bispecific antibodies, which simultaneously target CD3 on T cells and tumor-associated antigens to recruit cytotoxic T cells to cancer cells, are a promising new approach to the treatment of hormone-refractory prostate cancer. Here we report a site-specific, semisynthetic method for the production of bispecific antibody-like therapeutics in which a derivative of the prostate-specific membrane anti ...
- PubMed Central: